@article{oai:shiga-med.repo.nii.ac.jp:00003972,
 author = {小出, 博義 and 野田, 哲史 and 吉田, 哲也 and 影山, 進 and 寺村, 和也 and 加藤, 威 and 河内, 明宏 and 藤本, 徳毅 and 寺田, 智祐 and KOIDE, Hiroyoshi and NODA, Satoshi and YOSHIDA, Tetsuya and KAGEYAMA, Susumu and TERAMURA, Kazuya and KATO, Takeshi and KAWAUCHI, Akihiro and FUJIMOTO, Noriki and TERADA, Tomohiro},
 issue = {5},
 journal = {In vivo (Athens, Greece)},
 month = {Sep},
 note = {Background:
We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab., Case report:
Case 1: A 50-year-old man with RCC received nivolumab as the fifth-line therapy followed by sorafenib as the sixth-line therapy. On day 15 of sorafenib administration, the patient was hospitalized with systemic erythema multiforme, acne-like skin rash, and hand-foot syndrome. Case 2: A 40-year-old man with RCC received nivolumab as the second-line therapy followed by sorafenib as the fifth-line treatment. On day 12 of sorafenib administration, the patient was hospitalized with an acne-like skin rash and hand-foot syndrome. The skin disorders in the two cases improved within 2-3 weeks after sorafenib discontinuation and the start of treatment with topical and oral steroids., Conclusion:
When using sorafenib in patients previously treated with nivolumab, close attention should be paid to the onset of serious skin disorders., Journal Article},
 pages = {2969--2974},
 title = {Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients.},
 volume = {35},
 year = {2021}
}